Print

News

  • IGBA Reflection Paper on waiving bridging studies for biosimilar medicines applications

    IGBA proposes a new international biosimilars framework allowing bridging studies to be waived in specific circumstances based on core scientific and regulatory principles established for current products. Read More
  • IGBA Position on Identification of Biological, including Biosimilar Medicines 2018 Update of Facts & Figures

    IGBA Position on Identification of Biological, including Biosimilar Medicines 2018 Update of Facts & Figures. Read More
  • IGBA submission to HHS Blueprint to Lower Drug Prices and Reduce Out-of-Pocket Costs [RIN 0991-ZA49]

    16th July 2018. In its submission, IGBA invites the FDA to waive the requirement for bridging studies when a foreign-licensed reference comparator product is used for biosimilar development, given that the locally licensed reference product and the foreign-licensed product are Read More
  • Access, sustainability and manufacturing competitiveness highlighted at global generic, biosimilar and value added pharmaceutical conference in Budapest

    Budapest, 14th June 2018. Industry leaders from the generic, biosimilar and value added medicines industries discuss challenges and opportunities in ensuring sustainable, worldwide patient access to pharmaceuticals. Medicines for Europe and the International Generic and Biosimilar Medicines Association (IGBA) join Read More
  • IGBA Joins ICH Management Committee and Welcomes the Positive Vote of the General Assembly

    Tokyo, Japan (June 7, 2018) The International Generic and Biosimilar Medicines Association (IGBA) very much welcomes today’s decision of the ICH General Assembly to elect the IGBA as an Management Committee Member of the International Council for Harmonisation of Technical Read More
  • IGBA launches a biosimilar medicines information campaign

    February 01 2018 - Today, the International Generic and Biosimilar medicines Association (IGBA) launched an information campaign on biosimilar medicines. The foundation of this campaign is the IGBA biosimilar medicines public slide deck[1]. Access to well-referenced information is fundamental to improving Read More
  • IGBA congratulates the Australian government for maintaining their biologics naming convention and for strengthening pharmacovigilance

    January 29 2018 - The International Generic and Biosimilar medicines Association (IGBA) welcomes the Australian Government's decision to maintain the existing naming convention for biological, including biosimilar, medicines, that is to continue using the Australian biological name (without a specific identifier Read More
  • 1
  • 2
  • 3
  • 4
  • 5
  • 6

Joint 24th Medicines for Europe and 21st IGBA Annual Conference

Joint 23rd Medicines for Europe and 20th IGBA Annual Conference

Joint 22nd Medicines for Europe and 19th IGBA Annual Conference

Contact Info

IGBA | INTERNATIONAL GENERIC AND BIOSIMILAR MEDICINES ASSOCIATION

Rue d'Arlon, 50
B-1000 Brussels, Belgium

Telephone: +32 (0)2 736 84 11
Fax: +32 (0)2 736 74 38
E-mail: This email address is being protected from spambots. You need JavaScript enabled to view it.

We use cookies to improve our website and your experience when using it. Cookies used for the essential operation of the site have already been set. To find out more about the cookies we use and how to delete them, see our Privacy Policy.

I accept cookies from this site